IQVIA

IQV

Market cap $28.1B

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

IQVIA's AI push with NVIDIA, strategic deals and buybacks drive growth, but weakening liquidity raises concerns over near-term financial flexibility.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced at NVIDIA GTC the launch of IQVIA.ai, a unified agentic AI platform purpose-built to help life sciences organizations transform how they operate, make decisions and innovate across clinical, commercial and real-world domains. Combining IQVIA's deep life sciences expertise, Healthcare-grade AI® and.

IQVIA Holdings Inc. (IQV) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

IQVIA Holdings Inc. (IQV) Presents at Leerink Global Healthcare Conference 2026 Transcript

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Mike Fedock, executive vice president and chief financial officer, will speak at the Barclays 28th Annual Global Healthcare Conference on Thursday, March 12, 2026, at 9:30 a.m. ET. A live audio webcast of the presentation will be availa.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026, at 9:20 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA I.

IQVIA Holdings delivered strong Q4 and full-year 2025 results, confirming its leadership in data, analytics, and clinical execution. Despite macro headwinds and cautious biotech spending, IQV maintained robust profitability, near-100% cash conversion, and expanded its $32.7B backlog. EPS guidance for 2026 was below consensus, triggering a selloff, but I remain bullish due to durable bookings, backlog, and elite financial metrics.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today published its 2025 Sustainability Report. The report highlights IQVIA's progress across its People, Public and Planet pillars, consistent with the company's mission to accelerate innovation for a healthier world. IQVIA's 2025 Sustainability Report can be downl.